<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072886</url>
  </required_header>
  <id_info>
    <org_study_id>NP01</org_study_id>
    <nct_id>NCT05072886</nct_id>
  </id_info>
  <brief_title>Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Followed by an Open-Label Extension to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Topical AT193 in the Treatment of Patients With Nail Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azora Therapeutics Australia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azora Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 is a randomized, double-blind, placebo-controlled phase 1b study to evaluate AT193 in&#xD;
      approximately 30 patients with nail psoriasis for 16 weeks. Part 2 is an open-label extension&#xD;
      phase where all patients will receive active drug for an additional 16 weeks followed by a 2&#xD;
      week nontreatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nail Psoriasis</condition>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>AT193</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical applied daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical applied daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT193</intervention_name>
    <description>Topical</description>
    <arm_group_label>AT193</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of nail psoriasis for at least 3 months preceding study entry&#xD;
&#xD;
          -  Diagnosis or history of plaque psoriasis or psoriatic arthritis&#xD;
&#xD;
          -  A female participant of childbearing potential must use appropriate contraceptive&#xD;
             measures during the study period&#xD;
&#xD;
          -  A female participant of childbearing potential must have a negative urine pregnancy&#xD;
             test result at screening&#xD;
&#xD;
          -  Written informed consent must be obtained before any study procedure is performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Diagnosis of other active skin or nail diseases or skin or nail infections (bacterial,&#xD;
             fungal, or viral) that may interfere with evaluation of skin or fingernail psoriasis&#xD;
&#xD;
          -  History or evidence of a clinically significant disorder, condition, or disease that&#xD;
             would pose a risk to patient safety or interfere with the study evaluation,&#xD;
             procedures, or completion in the judgment of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matt Davidson, PhD</last_name>
    <phone>818-267-6726</phone>
    <email>matt@azoratherapeutics.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

